Table 3 Multivariate analyses of risk... | American Society of Hematology

Table 3

Multivariate analyses of risk factors for grades B-D AGVHD

Variable	SD				URD
Variable	n	OR	95% CI	P	n	OR	95% CI	P
Treatment category				< .0001				.0006
1: MA + TBI + PBSC	709	1.00			534	1.00
2: MA + TBI + BM	245	0.94	0.70-1.27	.69	733	0.71	0.56-0.91	.006
3: MA + nonTBI + PBSC	1017	0.97	0.80-1.18	.78	350	0.87	0.65-1.16	.34
4: MA + nonTBI + BM	492	0.56	0.44-0.71	< .0001	265	0.55	0.40-0.75	.0001
5: RIC + PBSC	622	0.70	0.56-0.88	.002	405	0.75	0.57-1.00	.05
6: RIC + BM	67	0.90	0.54-1.49	.67	83	0.47	0.29-0.76	.002
GVHD prophylaxis				.0001				.03
CSA + MTX ± other	2645	1.00			1208	1.00
Tacrolimus ± MTX ± other	484	0.65	0.53-0.80	< .0001	1140	0.79	0.67-0.94	.008
Other	23	0.54	0.21-1.39	.20	22	1.04	0.44-2.46	.94
Disease								.008
ALL					446	1.00
AML					1044	1.02	0.81-1.30	.85
CML					463	1.51	1.14-1.99	.004
MDS					417	1.12	0.83-1.49	.46
HLA match								.03
8/8 matched					1532	1.00
7/8 matched					614	1.27	1.05-1.54	.02
≤ 6/8 matched					224	1.26	0.94-1.68	.13

Variable	SD				URD
Variable	n	OR	95% CI	P	n	OR	95% CI	P
Treatment category				< .0001				.0006
1: MA + TBI + PBSC	709	1.00			534	1.00
2: MA + TBI + BM	245	0.94	0.70-1.27	.69	733	0.71	0.56-0.91	.006
3: MA + nonTBI + PBSC	1017	0.97	0.80-1.18	.78	350	0.87	0.65-1.16	.34
4: MA + nonTBI + BM	492	0.56	0.44-0.71	< .0001	265	0.55	0.40-0.75	.0001
5: RIC + PBSC	622	0.70	0.56-0.88	.002	405	0.75	0.57-1.00	.05
6: RIC + BM	67	0.90	0.54-1.49	.67	83	0.47	0.29-0.76	.002
GVHD prophylaxis				.0001				.03
CSA + MTX ± other	2645	1.00			1208	1.00
Tacrolimus ± MTX ± other	484	0.65	0.53-0.80	< .0001	1140	0.79	0.67-0.94	.008
Other	23	0.54	0.21-1.39	.20	22	1.04	0.44-2.46	.94
Disease								.008
ALL					446	1.00
AML					1044	1.02	0.81-1.30	.85
CML					463	1.51	1.14-1.99	.004
MDS					417	1.12	0.83-1.49	.46
HLA match								.03
8/8 matched					1532	1.00
7/8 matched					614	1.27	1.05-1.54	.02
≤ 6/8 matched					224	1.26	0.94-1.68	.13

Pairwise comparisons significant for the treatment categories were as follows for SD, treatment category 2 versus treatment category 4 (P = .003), treatment category 3 versus treatment category 4 (P < .0001), treatment category 3 versus treatment category 5 (P = .003); and for URD, treatment category 3 versus treatment category 4 (P = .006), and treatment category 3 versus treatment category 6 (P = .01).

CSA indicates cyclosporine; MTX, methotrexate; MDS, myelodysplastic syndrome; and MA, myeloablative.

View Large

This Feature Is Available To Subscribers Only